NEW YORK, NY, EpiBone, a leading regenerative medicine company at the forefront of skeletal repair, announces the successful close of a convertible note funding round.
EpiBone, a leading regenerative medicine company at the forefront of skeletal repair, announces the successful close of a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital plc, and others. This additional funding will propel EpiBone's ongoing pipeline development, furthering its mission to revolutionize skeletal reconstruction on a global scale.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
